文献速递类风湿关节炎

类风湿关节炎中改善病情抗风湿药与他汀类药物相关的糖尿病风险

Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2016-11-11

羟氯喹(HR 0.67)和阿巴西普(HR 0.52)与糖尿病风险降低相关,糖皮质激素(HR 1.31)和他汀类(HR 1.56)与风险升高相关。

要点

  • 类风湿关节炎患者糖尿病发病率高于美国成年人群。
  • 羟氯喹和阿巴西普与糖尿病风险降低相关,糖皮质激素和他汀类与风险升高相关。
  • 其他合成或生物改善病情抗风湿药未显示糖尿病风险改变。

核心结论

  • 在类风湿关节炎患者中,糖尿病发病率升高,羟氯喹和阿巴西普与糖尿病风险降低相关,糖皮质激素和他汀类与风险升高相关。

研究设计与样本

  • 研究纳入2000至2014年国家风湿病数据库参与至少1年且无基线糖尿病的类风湿关节炎患者,采用时变Cox比例风险模型调整年龄、性别、社会经济状态、合并症、体重指数和类风湿关节炎严重程度指标。

主要发现

  • 类风湿关节炎患者糖尿病标准化发病比(95%CI)为1.37(1.29-1.45),高于美国成年人群。
  • 与甲氨蝶呤单药治疗相比,阿巴西普调整后HR(95%CI)为0.52(0.31-0.89),羟氯喹为0.67(0.57-0.80)。
  • 糖皮质激素调整后HR(95%CI)为1.31(1.15-1.49),他汀类为1.56(1.36-1.78)。
  • 其他合成或生物改善病情抗风湿药与糖尿病风险无显著关联。

关键数值与推荐

  • 糖尿病由自我报告或启动降糖药物治疗确定。
  • 改善病情抗风湿药分为四组:甲氨蝶呤单药治疗(参照)、任何阿巴西普联合或不联合合成改善病情抗风湿药、其他改善病情抗风湿药联合甲氨蝶呤、所有其他改善病情抗风湿药不联合甲氨蝶呤。
  • 同时评估他汀类、糖皮质激素和羟氯喹(是/否)变量。
  • 糖皮质激素联用未改变羟氯喹对糖尿病风险的降低作用(HR 0.69,95%CI 0.51-0.93)。

临床怎么用

  • 对类风湿关节炎患者应关注糖尿病风险,尤其是使用糖皮质激素或他汀类药物的患者。
  • 羟氯喹和阿巴西普可能与糖尿病风险降低相关,可考虑在合适患者中选用。
  • 需结合患者个体情况权衡改善病情抗风湿药和糖皮质激素的获益与糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the rate of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) and the impact of disease-modifying antirheumatic drug (DMARD) and statin treatments. METHODS: We studied patients with RA and ≥1 year participation in the National Data Bank for Rheumatic Diseases without baseline DM from 2000 through 2014. DM was determined by self-report or initiating DM medication. DMARDs were categorised into four mutually exclusive groups: (1) methotrexate monotherapy (reference); (2) any abatacept with or without synthetic DMARDs (3) any other DMARDs with methotrexate; (4) all other DMARDs without methotrexate; along with separate statin, glucocorticoid and hydroxychloroquine (yes/no) variables. Time-varying Cox proportional hazard models were used to adjust for age, sex, socioeconomic status, comorbidities, body mass index and RA severity measures. RESULTS: During a median (IQR) 4.6 (2.5-8.8) years of follow-up in 13 669 patients with RA, 1139 incident DM cases were observed. The standardised incidence ratio (95% CI) of DM in patients with RA (1.37, (1.29 to 1.45)) was increased compared with US adult population. Adjusted HR (95% CI) for DM were 0.67 (0.57 to 0.80) for hydroxychloroquine, 0.52 (0.31 to 0.89) for abatacept (compared with methotrexate monotherapy), 1.31 (1.15 to 1.49) for glucocorticoids and 1.56 (1.36 to 1.78) for statins. Other synthetic/biological DMARDs were not associated with any risk change. Concomitant use of glucocorticoids did not alter DM risk reduction with hydroxychloroquine (HR 0.69 (0.51 to 0.93)). CONCLUSIONS: In RA, incidence of DM is increased. Hydroxychloroquine and abatacept were associated with decreased risk of DM, and glucocorticoids and statins with increased risk.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2016. PMID: 27836820. doi:10.1136/annrheumdis-2016-209954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。